No quarterly revenue total was found in Structure Therapeutics Inc.'s SEC filings.
Structure Therapeutics Inc. (GPCR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$120.2 million. As of Jun 30, 2026 it held $1.3 billion in cash and investments and $6.2 million in total debt.
Revenue
—
Net income
$-106.16M
-72.2% vs year-ago quarter
Operating cash flow
$-120.11M
-120.2% vs year-ago quarter
Free cash flow
$-120.16M
-119.3% vs year-ago quarter
EPS
$-0.49
-36.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
213.93M
+23.8% vs year-ago quarter
Net cash
$1.34B
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GPCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1888886
- Former names
- ShouTi Inc. (until May 13, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$118.6M | -$89.4M | $24.0M | -$73.8M | -$70.5M |
| Net income | -$106.2M | -$76.0M | $33.0M | -$65.7M | -$61.7M |
| Diluted EPS | -$0.49 | -$0.35 | $0.17 | -$0.37 | -$0.36 |
| Operating cash flow | -$120.1M | $15.2M | -$64.4M | -$51.0M | -$54.6M |
| Free cash flow | -$120.2M | $14.1M | -$65.9M | -$52.6M | -$54.8M |
| Total assets | $1.4B | $1.5B | $1.6B | $832.2M | $816.4M |
| Total liabilities | $71.0M | $61.0M | $67.5M | $62.1M | $44.4M |
| Stockholders' equity | $1.4B | $1.4B | $1.5B | $770.0M | $772.1M |
| Cash and investments | $1.3B | $1.5B | $1.4B | $799.0M | $786.5M |
| Total debt | $6.2M | $5.8M | $6.5M | $7.1M | $7.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
May 7, 2026 | May 7, 2026 |
All 271 Structure Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.